Results 71 to 80 of about 483,931 (267)

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

Histories in bone: Navigating the ethical landscape of human skeletal collections in South Africa

open access: yesAnatomical Sciences Education, EarlyView.
Abstract Provenance is at the center of addressing the complicated ethical stewardship of legacy human skeletal collections. Many South African (SA) health science institutions have skeletal collections. While the history of the collections and the demographics of the skeletons have been reported, the provenance of the individuals within the ...
Quenth Chinenere   +2 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

open access: yesHepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger   +7 more
wiley   +1 more source

Yellow fever resurgence: An avoidable crisis?

open access: yesnpj Vaccines, 2022
Nicole P. Lindsey   +10 more
doaj   +1 more source

Essential work, invisible workers: The role of digital curation in COVID‐19 Open Science

open access: yesJournal of the Association for Information Science and Technology, Volume 76, Issue 4, Page 703-717, April 2025.
Abstract In this paper, we examine the role digital curation practices and practitioners played in facilitating open science (OS) initiatives amid the COVID‐19 pandemic. In Summer 2023, we conducted a content analysis of available information regarding 50 OS initiatives that emerged—or substantially shifted their focus—between 2020 and 2022 to address ...
Irene V. Pasquetto   +2 more
wiley   +1 more source

Memorial of epidemics

open access: yesGlobal Rheumatology, 2022
From the memories of training as a medical student, the report of a patient, an octogenarian woman, black, small, skinny, very lively and communicative. She was happy to tell us, at the instigation of the neurology professor, what had happened to her during the Spanish in Porto Alegre.
openaire   +2 more sources

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Nest predation risk influences the Varied Tit’s life history strategy in response to temperature and precipitation

open access: yesJournal of Field Ornithology, 2022
Life history strategy is of great significance to the survival and reproduction of any individual because it determines individual fitness. Strategies are shaped by diverse factors: temperature, precipitation, and nest predation risks may be some of them.
Yiting Jiang   +3 more
doaj  

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy